Cantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating

Sara Nik, an analyst from H.C. Wainwright, has initiated a new Buy rating on Cantargia AB (7V3).

Sara Nik’s rating is based on Cantargia AB’s promising pipeline in both oncology and autoimmune indications. The company’s lead asset, nadunolimab, is being tested in several challenging cancers, including metastatic pancreatic ductal adenocarcinoma (PDAC), where it shows potential to compete with existing treatments if its mechanism proves effective. This positions Cantargia to offer multiple value drivers to investors, making it an attractive long-term investment.
Additionally, the acquisition of Cantargia’s CAN10 program by Otsuka Pharmaceutical provides significant external validation and financial support. This deal not only brings upfront cash but also potential milestone payments and royalties, allowing Cantargia to focus on its core strengths while reducing its R&D burden. The strategic partnership with Otsuka enhances Cantargia’s financial stability and supports further development of its promising oncology programs, contributing to the Buy rating.